Literature DB >> 15136683

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

Z Walker1, D C Costa, R W H Walker, L Lee, G Livingston, E Jaros, R Perry, I McKeith, C L E Katona.   

Abstract

OBJECTIVE: To study the nigrostriatal pathways in 21 patients with dementia with Lewy bodies (DLB), 19 drug naive Parkinson disease (PD) patients, and 16 controls using a dopaminergic presynaptic ligand [123I]-2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT) and SPECT in order to assess similarities or differences between DLB and PD.
METHODS: A SPECT scan was carried out 3 to 4 hours after administration of 185 MBq (IV) of FP-CIT. Using occipital cortex as a radioactivity uptake reference, ratios for the caudate nuclei and the anterior and posterior putamina of both hemispheres were calculated. From the FP-CIT binding measurements, asymmetry indices and caudate:putamen ratios were derived.
RESULTS: The DLB and PD groups had lower FP-CIT binding in all striatal areas than controls (analysis of variance: p < 0.001 in all measures). DLB patients also had significantly lower binding in the caudate nucleus than the PD patients. There was greater asymmetry of uptake in the posterior putamina of PD patients than DLB patients (p < 0.04) and controls (p < 0.01). The mean caudate:putamen ratio for the DLB group was not significantly different from that of the controls, while the mean caudate:putamen ratio of the PD group was higher than that of the control group (p < 0.001) and the DLB group (p < 0.001).
CONCLUSION: This study showed differences between PD and DLB in the pattern of striatal dopaminergic dysfunction. DLB patients do not have the characteristic selective degeneration of ventrolateral nigral neurons seen in PD. This could explain some of the clinical differences between DLB and PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136683     DOI: 10.1212/01.wnl.0000123248.39847.1d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

2.  Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Authors:  Sean J Colloby; E David Williams; David J Burn; Jim J Lloyd; Ian G McKeith; John T O'Brien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-02       Impact factor: 9.236

Review 3.  Imaging of the dopaminergic system in differential diagnosis of dementia.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 4.  Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.

Authors:  Tingting Tang; Yong Li; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Neurosci Bull       Date:  2017-03-23       Impact factor: 5.203

Review 5.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

6.  Metabolic connectomics targeting brain pathology in dementia with Lewy bodies.

Authors:  Silvia P Caminiti; Marco Tettamanti; Arianna Sala; Luca Presotto; Sandro Iannaccone; Stefano F Cappa; Giuseppe Magnani; Daniela Perani
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 7.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

8.  Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Authors:  Lidia Sarro; Matthew L Senjem; Emily S Lundt; Scott A Przybelski; Timothy G Lesnick; Jonathan Graff-Radford; Bradley F Boeve; Val J Lowe; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Brain       Date:  2016-07-24       Impact factor: 13.501

9.  Performance of a high-sensitivity dedicated cardiac SPECT scanner for striatal uptake quantification in the brain based on analysis of projection data.

Authors:  Mi-Ae Park; Stephen C Moore; Stefan P Müller; Sarah J McQuaid; Marie Foley Kijewski
Journal:  Med Phys       Date:  2013-04       Impact factor: 4.071

10.  The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.

Authors:  Angelo Antonini
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.